Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics, Inc. (STOK) Healthcare & Pipeline Overview

Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company pioneering antisense oligonucleotide (ASO) medicines. Utilizing its proprietary TANGO platform, Stoke focuses on upregulating protein expression to address severe genetic diseases, with lead candidates STK-001 for Dravet syndrome in Phase I/IIa and STK-002 for autosomal dominant optic atrophy.

What Is the Investment Thesis for STOK?

Stoke Therapeutics, Inc. presents a research focus centered on its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform, which is designed to precisely upregulate protein expression to treat severe genetic diseases. The company's lead candidate, STK-001, is in a Phase I/IIa clinical trial for Dravet syndrome, a significant unmet medical need, representing a key potential value driver. The progression of STK-001 through clinical development and potential positive data readouts are critical catalysts. Furthermore, the preclinical development of STK-002 for autosomal dominant optic atrophy expands the pipeline's future potential. The strategic collaboration with Acadia Pharmaceuticals Inc. provides external validation of Stoke's technology and offers additional resources for developing RNA-based medicines for neurodevelopmental diseases. While the company operates with a substantial negative profit margin of -529.2% and a market capitalization of $2.01B, typical for early-stage biotechnology firms focused on research and development, its high gross margin of 90.4% suggests strong potential profitability if product development is successful. The company's beta of 1.20 indicates higher volatility relative to the market, reflecting the inherent risks of clinical-stage biopharmaceutical development.

Based on FMP financials and quantitative analysis

STOK Key Highlights

• Market capitalization stands at $1.87 billion, reflecting its valuation as an early-stage biotechnology company.
• Reported a significant negative profit margin of -529.2%, indicative of substantial investment in research and development activities.
• Achieved a gross margin of 90.4%, which is characteristic of a biopharmaceutical company with collaboration revenue or pre-commercial stage operations.
• The lead clinical candidate, STK-001, is actively progressing through Phase I/IIa clinical trials for Dravet syndrome.
• Maintains a beta of 1.20, suggesting higher volatility compared to the broader market, consistent with its industry sector.

Who Are STOK's Competitors?

STOK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are STOK's Key Strengths?

• Proprietary TANGO platform offers a unique mechanism of action (protein upregulation) for genetic diseases.
• Lead clinical candidate, STK-001, is in Phase I/IIa trials for a severe, unmet medical need (Dravet syndrome).
• Strategic collaboration with Acadia Pharmaceuticals Inc. provides validation and resources.
• High gross margin of 90.4% indicates strong potential profitability if products reach market.

What Are STOK's Weaknesses?

• Early-stage company with a limited product pipeline, heavily reliant on the success of STK-001 and STK-002.
• Significant negative profit margin (-529.2%) reflects high R&D costs and lack of commercialized products.
• Dependency on successful clinical trial outcomes and regulatory approvals, which are inherently uncertain.
• No current revenue from product sales, relying on collaborations and capital raises for operations.

What Could Drive STOK Stock Higher?

• Progress and data readouts from the Phase I/IIa clinical trial of STK-001 for Dravet syndrome, which could provide key insights into its efficacy and safety profile.
• Advancement of STK-002 from preclinical development into initial clinical trials for autosomal dominant optic atrophy, signaling pipeline progression.
• Continued development and potential expansion of the collaboration with Acadia Pharmaceuticals Inc. for novel RNA-based medicines, potentially leading to milestone achievements.
• Identification and initiation of new development programs utilizing the proprietary TANGO platform for additional severe genetic diseases, diversifying the pipeline.

What Are the Key Risks for STOK?

• Negative return on equity (-48.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected adverse events for STK-001 or STK-002, which could significantly impact the company's valuation and future prospects.
• Significant negative profit margin of -529.2% indicates substantial cash burn and a continued need for financing to sustain operations and R&D.
• Regulatory hurdles and delays in obtaining necessary approvals from health authorities for its drug candidates, extending development timelines and increasing costs.
• Intense competition within the biotechnology sector for genetic disease therapies, potentially impacting market share and pricing power upon commercialization.
• Reliance on the successful development of a limited number of early-stage drug candidates, making the company highly susceptible to pipeline setbacks.

What Are the Growth Opportunities for STOK?

• **Advancement of STK-001 for Dravet Syndrome:** STK-001, currently in Phase I/IIa clinical trials, represents a significant growth opportunity. Dravet syndrome is a severe, lifelong form of epilepsy with limited treatment options, creating a substantial unmet medical need. The global market for Dravet syndrome treatments is projected to grow, driven by increasing diagnosis rates and demand for more effective therapies. Successful progression through clinical trials and eventual regulatory approval for STK-001 could establish Stoke as a leader in this therapeutic area, potentially generating significant revenue streams within the next 5-10 years, assuming a typical drug development timeline.
• **Development of STK-002 for Autosomal Dominant Optic Atrophy:** The preclinical development of STK-002 targets autosomal dominant optic atrophy, a rare genetic eye disorder leading to progressive vision loss. This represents another area of high unmet medical need with no approved disease-modifying treatments. Advancing STK-002 into clinical trials and demonstrating efficacy could unlock a new therapeutic market for Stoke. The potential market for rare ophthalmic genetic diseases, while niche, commands premium pricing due to the severity and lack of alternatives, offering a long-term growth pathway over the next decade.
• **Expansion of the TANGO Platform to New Indications:** Stoke's proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform is designed to upregulate protein expression, offering broad applicability beyond its current lead candidates. The company has the opportunity to leverage this platform to identify and develop ASO medicines for a wider range of severe genetic diseases caused by haploinsufficiency. This platform-based approach allows for the systematic expansion of its pipeline, potentially addressing multiple rare disease markets. Each new indication represents a distinct growth opportunity, with the potential to add new revenue streams over a 5-15 year horizon as new programs enter development.
• **Strategic Collaboration with Acadia Pharmaceuticals Inc.:** The license and collaboration agreement with Acadia Pharmaceuticals Inc. for RNA-based medicines targeting severe and rare genetic neurodevelopmental diseases of the central nervous system provides a strategic growth avenue. This partnership not only validates Stoke's technology but also provides access to additional resources, expertise, and potential milestone payments and royalties. Expanding the scope of this collaboration or forming new partnerships with other pharmaceutical companies could accelerate pipeline development and broaden market reach, contributing to growth over the next 3-7 years through shared development costs and commercialization potential.
• **Growth in the Broader Antisense Oligonucleotide (ASO) Market:** The overall market for antisense oligonucleotide therapies is experiencing robust growth due to their precision targeting capabilities and increasing understanding of genetic diseases. As ASO technology matures and regulatory pathways become clearer, the adoption of these medicines is expected to rise. Stoke, with its specialized TANGO platform, is well-positioned to capitalize on this broader industry trend. Continued innovation in ASO design and delivery mechanisms could enhance the efficacy and safety profile of Stoke's therapies, further expanding their market potential and contributing to sustained growth over the next decade.

What Opportunities Does STOK Have?

• Expansion of the TANGO platform to address a broader range of genetic diseases beyond current pipeline candidates.
• Successful progression and positive data from STK-001 and STK-002 clinical trials.
• Formation of additional strategic partnerships and collaborations to accelerate development and expand market reach.
• Capitalizing on the growing market for ASO therapies and precision medicines for rare diseases.

What Threats Does STOK Face?

• Risk of clinical trial failures, delays, or unexpected adverse events for lead candidates.
• Intense competition from other biopharmaceutical companies developing therapies for genetic diseases.
• Regulatory hurdles and the lengthy, complex process of obtaining drug approvals.
• Intellectual property challenges and the need to maintain patent protection for proprietary technologies.
• Need for significant ongoing funding to support research, development, and commercialization efforts.

What Are STOK's Competitive Advantages?

• Proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform for upregulating protein expression.
• Specialized expertise in designing antisense oligonucleotide (ASO) medicines for genetic diseases.
• Targeting rare and severe genetic diseases with high unmet medical needs, potentially leading to orphan drug designations.
• Early-stage clinical development of lead candidates like STK-001 for Dravet syndrome.

What Does STOK Do?

Stoke Therapeutics, Inc., incorporated in 2014 and headquartered in Bedford, Massachusetts, is an early-stage biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) medicines. The company's core mission is to address the underlying causes of severe genetic diseases within the United States, focusing on conditions where current treatment options are limited or non-existent. Stoke's foundational technology is its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform. This advanced platform is specifically designed to create ASOs that precisely upregulate protein expression, offering a novel approach to treating genetic disorders caused by insufficient protein levels. The company's pipeline features several promising candidates. Its lead clinical candidate, STK-001, is currently undergoing a Phase I/IIa clinical trial for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. This condition presents significant challenges for patients and caregivers, highlighting the unmet medical need Stoke aims to address. In addition to STK-001, Stoke Therapeutics is advancing STK-002, which is in the preclinical stage of development for autosomal dominant optic atrophy, another severe genetic condition affecting vision. The company's strategic growth is further bolstered by a license and collaboration agreement with Acadia Pharmaceuticals Inc. This partnership focuses on the discovery, development, and commercialization of novel RNA-based medicines specifically for severe and rare genetic neurodevelopmental diseases of the central nervous system. Originally known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016, marking its evolution and strategic focus in the biopharmaceutical landscape.

What Products and Services Does STOK Offer?

• Develops novel antisense oligonucleotide (ASO) medicines.
• Focuses on treating the underlying causes of severe genetic diseases.
• Utilizes a proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform.
• Designs ASOs to precisely upregulate protein expression.
• Has a lead clinical candidate, STK-001, for Dravet syndrome in Phase I/IIa trials.
• Is developing STK-002 for autosomal dominant optic atrophy in preclinical stages.
• Collaborates with Acadia Pharmaceuticals Inc. for RNA-based neurodevelopmental disease medicines.

How Does STOK Make Money?

• Primarily focused on research and development of proprietary ASO medicines for genetic diseases.
• Potential future revenue generation from the commercialization and sales of approved drug products.
• Receives funding and potential milestone payments/royalties from strategic collaborations, such as with Acadia Pharmaceuticals Inc.
• Relies on capital raises and partnerships to fund extensive clinical development programs.

What Industry Does STOK Operate In?

Stoke Therapeutics operates within the highly specialized and innovative Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by extensive research and development, long product development cycles, and significant regulatory hurdles. Stoke's focus on antisense oligonucleotide (ASO) medicines for severe genetic diseases places it in a niche with substantial unmet medical needs. The broader ASO market is experiencing growth, driven by advancements in genetic understanding and drug delivery technologies. Competition within the biotechnology space is intense, with numerous companies pursuing novel therapies for rare diseases. Stoke differentiates itself through its proprietary TANGO platform, which aims to address diseases by upregulating protein expression, a distinct mechanism compared to gene silencing or replacement therapies. The company's early-stage pipeline, particularly in Dravet syndrome and autosomal dominant optic atrophy, positions it to potentially capture market share in these specific therapeutic areas, contingent upon successful clinical development and regulatory approval.

Who Are STOK's Key Customers?

• Patients suffering from severe genetic diseases like Dravet syndrome and autosomal dominant optic atrophy.
• Healthcare providers and institutions seeking advanced treatments for rare genetic disorders.
• Pharmaceutical partners interested in co-developing or licensing novel RNA-based therapies.

How Stoke Therapeutics, Inc. Is Valued

Stoke Therapeutics, Inc. carries a market capitalization of $2.01B, placing it in the mid-cap category. Relative to its peer group, STOK's quantitative score of 23/100 is below the peer average of 78/100.

Company Profile

Stoke Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bedford, US. The company is led by CEO Ian F. Smith. STOK has traded publicly since 2019.

ROE -49%Key Financial Metrics

Return on equity for Stoke Therapeutics, Inc. stands at -48.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -38.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.99 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Stoke Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 23.22 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Stoke Therapeutics, Inc. revenue of about $27.7M for fiscal 2026, with EPS near $-3.29. The estimate reflects 8 contributing analysts.

Net buyingInsider Activity

Over the past six months, Stoke Therapeutics, Inc. insiders filed 29 SEC Form 4 transactions — 20 sales and 9 purchases. On net that is roughly 118K shares acquired (about $3.5M) — insiders putting money in tends to read as conviction.

STOK Financials

STOK Latest News

STOK Analyst Consensus

STOK MoonshotScore

Stoke Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources